RA Capital Management - Q1 2023 holdings

$4.42 Billion is the total value of RA Capital Management's 59 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 27.1% .

 Value Shares↓ Weighting
ASND  ASCENDIS PHARMA A/S$745,948,732
-12.2%
6,957,1790.0%16.89%
-2.0%
PCVX BuyVAXCYTE INC$273,276,200
-2.7%
7,291,254
+24.5%
6.19%
+8.6%
BuyDICE THERAPEUTICS INC$225,091,934
+5.3%
7,856,612
+14.7%
5.10%
+17.6%
ETNB Buy89BIO INC$173,880,118
+52.5%
11,416,948
+27.5%
3.94%
+70.2%
AVTE  AEROVATE THERAPEUTICS INC$166,684,517
-31.2%
8,263,9820.0%3.77%
-23.2%
BIIB  BIOGEN INC$148,159,963
+0.4%
532,8920.0%3.35%
+12.1%
VRNA  VERONA PHARMA PLC$126,865,239
-23.2%
6,317,9900.0%2.87%
-14.2%
 CYTEK BIOSCIENCES INCsponsored adr$122,971,886
-10.0%
13,381,0540.0%2.78%
+0.5%
VOR  VOR BIOPHARMA INC$122,388,974
-19.1%
22,748,8800.0%2.77%
-9.7%
LEGN  LEGEND BIOTECH CORP$117,474,673
-3.4%
2,436,2230.0%2.66%
+7.8%
 TYRA BIOSCIENCES INC$116,289,816
+111.4%
7,236,4540.0%2.63%
+136.1%
JANX  JANUX THERAPEUTICS INC$104,914,792
-8.1%
8,670,6440.0%2.38%
+2.5%
 PEPGEN INC$99,453,773
-8.5%
8,131,9520.0%2.25%
+2.1%
RNA BuyAVIDITY BIOSCIENCES INC$98,500,919
-18.6%
6,416,998
+17.6%
2.23%
-9.2%
RYTM  RHYTHM PHARMACEUTICALS INC$98,406,635
-38.7%
5,516,0670.0%2.23%
-31.6%
DAWN  DAY ONE BIOPHARMACEUTICALS I$94,133,116
-37.9%
7,040,6220.0%2.13%
-30.7%
BLU BuyBELLUS HEALTH INC NEW$91,033,733
-11.1%
12,643,574
+1.5%
2.06%
-0.7%
CVAC NewCUREVAC N Vsponsored ads$85,354,30612,245,955
+100.0%
1.93%
IMGN  IMMUNOGEN INC$83,919,199
-22.6%
21,853,9580.0%1.90%
-13.6%
WVE  WAVE LIFE SCIENCES LTD$74,484,699
-38.1%
17,202,0090.0%1.69%
-31.0%
INBX  INHIBRX INC$72,722,470
-23.4%
3,853,8670.0%1.65%
-14.5%
GERN BuyGERON CORPads$68,452,229
+118.8%
31,544,806
+144.0%
1.55%
+144.1%
COGT  COGENT COMMUNICATIONS HLDGS$64,734,400
-6.7%
5,999,4810.0%1.46%
+4.1%
CLDX SellCELLDEX THERAPEUTICS INC NEW$62,424,293
-32.5%
1,734,972
-16.4%
1.41%
-24.7%
 ACRIVON THERAPEUTICS INC$61,045,347
+10.2%
4,810,5080.0%1.38%
+23.0%
ITOS  ITEOS THERAPEUTICS INCsponsored adr$60,118,895
-30.3%
4,417,2590.0%1.36%
-22.2%
 NEWAMSTERDAM PHARMA COMPANY$53,040,000
+21.7%
4,000,0000.0%1.20%
+35.9%
VRDN BuyVIRIDIAN THERAPEUTICS INC$51,082,146
+98.7%
2,007,946
+128.2%
1.16%
+121.9%
 RXSIGHT INCordinary shares$50,920,637
+31.6%
3,052,7960.0%1.15%
+47.1%
NewMINERALYS THERAPEUTICS INC$49,774,9343,178,476
+100.0%
1.13%
PLRX NewPLIANT THERAPEUTICS INC$46,869,2001,762,000
+100.0%
1.06%
NewENLIVEN THERAPEUTICS INC$46,481,9842,122,465
+100.0%
1.05%
GHRS BuyGH RESEARCH PLC$44,593,476
-6.3%
5,581,161
+13.9%
1.01%
+4.5%
ABOS  ACUMEN PHARMACEUTICALS INCsponsored ads$39,669,338
-24.8%
9,770,7730.0%0.90%
-16.1%
 ELIEM THERAPEUTICS INC$38,137,462
-21.0%
13,150,8490.0%0.86%
-11.8%
 AN2 THERAPEUTICS INC$37,244,613
+3.6%
3,773,5170.0%0.84%
+15.6%
ALPN BuyALPINE IMMUNE SCIENCES INC$36,192,248
+12.0%
4,688,115
+6.6%
0.82%
+25.0%
ACRS  ACLARIS THERAPEUTICS INC$35,583,485
-48.6%
4,398,4530.0%0.81%
-42.6%
 ICOSAVAX INC$34,588,677
-27.0%
5,963,5650.0%0.78%
-18.4%
FULC BuyFULCRUM THERAPEUTICS INC$33,087,656
-52.2%
11,609,704
+22.1%
0.75%
-46.7%
 HILLEVAX INC$29,093,114
-1.2%
1,760,0190.0%0.66%
+10.4%
NKTX  NKARTA INC$27,708,208
-40.7%
7,805,1290.0%0.63%
-33.9%
KNTE  KINNATE BIOPHARMA INC$26,650,900
+2.5%
4,264,1440.0%0.60%
+14.2%
NSTG BuyNANOSTRING TECHNOLOGIES$24,327,003
+2021.1%
2,457,273
+1607.6%
0.55%
+2295.7%
SBTX  ARS PHARMACEUTICALS INC$19,593,004
-23.7%
3,009,6780.0%0.44%
-14.8%
RCKT SellROCKET PHARMACEUTICALS INC$19,387,306
-58.8%
1,131,775
-53.0%
0.44%
-54.0%
 TENAYA THERAPEUTICS INC$17,292,327
+41.8%
6,067,4830.0%0.39%
+58.3%
DSGN  DESIGN THERAPEUTICS INC$17,144,003
-43.8%
2,971,2310.0%0.39%
-37.2%
 SOLID BIOSCIENCES INC$16,240,596
-11.9%
3,426,2860.0%0.37%
-1.6%
HOWL BuyWEREWOLF THERAPEUTICS INC$15,976,691
+81.6%
6,144,881
+43.2%
0.36%
+103.4%
CELC  CELCUITY INC$14,350,010
-26.8%
1,400,0010.0%0.32%
-18.3%
EYPT  EYEPOINT PHARMACEUTICALS INC$9,909,288
-16.0%
3,370,5060.0%0.22%
-6.3%
CNTB  CONNECT BIOPHARMA HLDGS LTD$6,990,304
+15.2%
6,991,0030.0%0.16%
+28.5%
BDTX  BLACK DIAMOND THERAPEUTICS I$4,894,919
+5.0%
2,589,9040.0%0.11%
+16.8%
 AADI BIOSCIENCE INC$4,273,178
-43.6%
590,2180.0%0.10%
-37.0%
STSA  SATSUMA PHARMACEUTICALS INC$4,131,105
-22.4%
5,914,2520.0%0.09%
-13.0%
FUSN  FUSION PHARMACEUTICALS INC$2,488,170
+19.7%
659,9920.0%0.06%
+33.3%
 NEWAMSTERDAM PHARMA COMPANY*w exp 11/22/202$613,333
+111.9%
333,3330.0%0.01%
+133.3%
ENTX  ENTERA BIO LTD$343,321
+58.9%
295,9660.0%0.01%
+100.0%
IMUX ExitIMMUNIC INC$0-632,184
-100.0%
-0.02%
ACHL ExitACHILLES THERAPEUTICS PLCsponsored ads$0-1,607,834
-100.0%
-0.03%
ExitTHIRD HARMONIC BIO INC$0-534,687
-100.0%
-0.05%
ExitIO BIOTECH INC$0-1,127,260
-100.0%
-0.05%
DBVT ExitDBV TECHNOLOGIES S Asponsored adr$0-1,958,957
-100.0%
-0.06%
CVRX ExitCVRX INC$0-275,000
-100.0%
-0.10%
ATHA ExitATHIRA PHARMA INC$0-1,881,300
-100.0%
-0.12%
HSAQ ExitHEALTH SCIENCES ACQ CORP 2$0-610,283
-100.0%
-0.12%
CNCE ExitCONCERT PHARMACEUTICALS INC$0-1,088,296
-100.0%
-0.13%
ExitARYA SCIENCES ACQUISITN CORP$0-1,000,000
-100.0%
-0.20%
IMRA ExitIMARA INC$0-3,250,724
-100.0%
-0.27%
SCPH ExitSCPHARMACEUTICALS INC$0-1,856,904
-100.0%
-0.27%
ExitDA32 LIFE SCNCE$0-1,500,000
-100.0%
-0.30%
AKRO ExitAKERO THERAPEUTICS INC$0-958,980
-100.0%
-1.07%
TVTX ExitTRAVERE THERAPEUTICS INC$0-3,984,681
-100.0%
-1.70%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-05-15
Signatures

The EDGAR filing(s) were signed by:

About RA Capital Management

RA Capital Management is a Boston-based investment management firm that specializes in the healthcare sector. The firm was founded in 2001 by Peter Kolchinsky, a former biotech analyst at Lehman Brothers. Since then, RA Capital has grown to become one of the most respected healthcare investment firms in the world, with over $5 billion in assets under management.

The firm's investment strategy is focused on identifying and investing in companies that are developing innovative therapies and technologies that have the potential to transform the healthcare industry. RA Capital's team of experienced analysts and portfolio managers conduct extensive research and due diligence to identify the most promising investment opportunities in the healthcare sector.

RA Capital's portfolio includes a diverse range of companies, from early-stage startups to established biotech and pharmaceutical companies. Some of the notable companies in RA Capital's portfolio include Moderna, a biotech company that is developing a COVID-19 vaccine, and Intellia Therapeutics, a gene editing company that is developing therapies for genetic diseases.

Peter Kolchinsky, the founder and CEO of RA Capital, is a well-respected figure in the healthcare investment community. He is a frequent speaker at industry conferences and has authored several books on biotech investing. Other key members of RA Capital's management team include Rajeev Shah, the firm's COO, and Derek DiRocco, the Chief Investment Officer.

Overall, RA Capital Management is a highly respected investment firm that has a proven track record of identifying and investing in innovative healthcare companies. Investors who are interested in the healthcare sector may want to consider RA Capital as a potential investment opportunity.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
ASCENDIS PHARMA A/S - ADR35Q3 202325.5%
WAVE LIFE SCIENCES PTE LTD32Q3 202326.3%
TG THERAPEUTICS INC30Q4 20216.3%
ZOGENIX INC26Q4 20219.5%
BIOCRYST PHARMACEUTICALS23Q1 20199.2%
DICERNA PHARMACEUTICALS INC23Q3 20195.8%
RHYTHM PHARMACEUTICALS INC22Q3 20234.4%
ACHILLION PHARMACEUTICALS INC19Q4 201717.2%
KALA PHARMACEUTICALS INC19Q1 20224.4%
SOLID BIOSCIENCES INC19Q3 20226.8%

View RA Capital Management's complete holdings history.

Latest significant ownerships (13-D/G)
RA Capital Management Q1 2023 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
ARS Pharmaceuticals, Inc.September 25, 20239,459,6789.9%
CymaBay Therapeutics, Inc.September 22, 20236,940,0006.2%
Cytek Biosciences, Inc.September 19, 20236,809,4045.0%
BELLUS Health Inc.Sold outAugust 14, 202300.0%
Kinnate Biopharma Inc.Sold outAugust 14, 202300.0%
Vor Biopharma Inc.August 11, 202322,780,34333.7%
DICE Therapeutics, Inc.Sold outAugust 09, 202300.0%
Acumen Pharmaceuticals, Inc.July 25, 202314,981,61825.9%
Talaris Therapeutics, Inc.July 06, 20232,333,1755.5%
Aerovate Therapeutics, Inc.June 27, 20238,293,14830.0%

View RA Capital Management's complete significant-ownership history.

Latest filings
TypeFiled
SC 13G2024-02-22
SC 13D/A2024-02-21
42024-02-20
13F-HR2024-02-14
42024-02-14
SC 13D/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View RA Capital Management's complete filings history.

Compare quarters

Export RA Capital Management's holdings